Search alternatives:
changed decrease » marked decrease (Expand Search), change increases (Expand Search), caused decreased (Expand Search)
larger decrease » marked decrease (Expand Search)
significant use » significant cause (Expand Search), significant i.e (Expand Search), significantly used (Expand Search)
use decreased » use increased (Expand Search), rate decreased (Expand Search), cost decreased (Expand Search)
Showing 121 - 140 results of 59,120 for search '(( significantly ((changed decrease) OR (larger decrease)) ) OR ( significant use decreased ))', query time: 1.34s Refine Results
  1. 121
    Consolidation of training-induced changes in unipedal stance: Path Length, X Sway Amplitude and Velocity.

    Consolidation of training-induced changes in unipedal stance: Path Length, X Sway Amplitude and Velocity. by Cristina Dolciotti (16317330)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 122
    Significantly changed USSs in the sf3b1 mutants.

    Significantly changed USSs in the sf3b1 mutants. by Bei Zhang (428038)

    Published 2021
    Save to List
    Saved in:
  3. 123
    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  4. 124
    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  5. 125
    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 126
    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of sulfamethoxazole-trimethoprim therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 127
    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 128
    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4.

    Average purchase costs of 3GCs and all oral antimicrobials per 100 patient-days from Phases 1–4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 129
    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 130
    S1 Dataset -

    S1 Dataset - by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 131
    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 132
    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  13. 133
    Pop-up for oral 3GC prescription.

    Pop-up for oral 3GC prescription. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  14. 134
    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 135
    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  16. 136
    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).

    Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  17. 137
    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  18. 138
    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4.

    Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  19. 139
    Cohesion characteristics and statistical significance analysis of different ingredients across IDDSI levels<sup>b'*'</sup>.

    Cohesion characteristics and statistical significance analysis of different ingredients across IDDSI levels<sup>b'*'</sup>. by Muxi Chen (9294270)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 140
    Adhesion characteristics and statistical significance analysis of different ingredients across IDDSI levels<sup>b'*'</sup>.

    Adhesion characteristics and statistical significance analysis of different ingredients across IDDSI levels<sup>b'*'</sup>. by Muxi Chen (9294270)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: